Hypertension drug “Mykardis” stopped being supplied to Russia

In Russian pharmacies, there was a shortage of the original medicine “Mykardis”, which is produced by the German company Boehringer Ingelheim. This was reported by “Vedomosti” with reference to an employee of one of the pharmaceutical companies. This drug of the latest generation is prescribed for arterial hypertension and, unlike analogs, almost does not cause side effects.

According to the aggregator “Megaptek”, “Mykardis” is not available in pharmacies in Moscow and the Moscow region, Nizhny Novgorod, Volgograd and Saratov. The situation with a shortage of the drug was also confirmed by the regional network “Apteka 25” and the federal “Rigle”.

Boehringer Ingelheim did not officially announce the termination of work in Russia. At the same time, as Roszdravnadzor told the publication, the Russian subsidiary of the German company notified the federal service in July of last year about the termination of the import of “Mykardis” and “Mykardis-plus” drugs into the country.

Roszdravnadzor assures that the Boehringer Ingelheim company’s decision to stop importing the drug “Mykardis” into Russia does not affect the availability of drugs with the active ingredient telmisartan in the country.

Earlier it was reported that the antidepressant “Prozac” also disappeared from Russian pharmacies. In addition, patients with cystic fibrosis complained about the lack of the vital drug “Pulmozym” in Russia. An available analogue is contraindicated in some patients.

According to the analytical company DSM Group, since the beginning of the year, the assortment of imported drugs in Russian pharmacies has decreased by 20 percent.